Company intelligence / Profile preview

ARTCLINE GmbH

Rostock, Mecklenburg-Vorpommern, Germany

Ownership: Private
Development stage: Phase 2

Overview

The company’s lead program, ARTICE®, has demonstrated clinical benefit in two scientific studies. It is currently being evaluated for effectiveness and safety in a large randomized controlled multicenter trial (ReActIF–ICE) enrolling 142 patients across approximately 20 intensive care centers in Germany. Regulatory approvals have been obtained for market readiness; final clinical validation is underway.

Therapeutic areas: Infectious Diseases
Modalities: Immune cell-based therapies (allogenic immune cells/extracorporeal therapy)
Industry: Biotech

Drug pipeline

2 assets

ARTICE

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with University of Rostock and leading intensive care centers across Germany for the ReActIF–ICE study; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on ARTCLINE GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTCLINE GmbH.

Explore the full profile